Gastroenterology

Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?

September 17th 2023

By Skylar Jeremias

On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.

Fran Gregory Weighs In on the Value of Interchangeability in the Adalimumab Market

September 10th 2023

By Skylar Jeremias

Video

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, explains the value of interchangeability in the adalimumab space and predicts whether interchangeable biosimilars will become leaders in adoption.

CVS Launches New Biosimilars Brand

September 6th 2023

By Skylar Jeremias

Article

CVS Health Corporation launched Cordavis, a new subsidiary that will work with manufacturers to commercialize and coproduce biosimilars, beginning with an adalimumab product.

Higher Risk of Discontinuation During Biosimilar Switching Found Among Women

September 5th 2023

By Justina Petrullo

Article

Switching from reference to biosimilar adalimumab was found to be safe and effective. Researchers cautioned that female patients may be at higher risk of discontinuation compared with their male counterparts.

Meta-Analysis Confirms Clinical Equivalence Between RA Biosimilars, Originators

August 26th 2023

By Skylar Jeremias

Article

A meta-analysis and systematic review of data on over 10,000 patients with rheumatoid arthritis (RA) found that etanercept, adalimumab, and infliximab biosimilars were clinically equivalent to their reference products.

FDA Approves First MS Biosimilar

August 25th 2023

By Skylar Jeremias

Article

The FDA approved its first biosimilar indicated for multiple sclerosis (MS), Sandoz’ Tyruko (natalizumab-sztn), a biosimilar referencing Tysabi (natalizumab).

Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry

August 23rd 2023

By Skylar Jeremias

Article

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, published her opinions on the future of biosimilars in the United States, foreshadowing immense growth and a transformation of the US health care industry thanks to biosimilars.

Research Confirms Long-Term Stability of Adalimumab Biosimilar Candidate TUR01

August 12th 2023

By Deana Ferreri, PhD

Article

A study on the stability of the adalimumab biosimilar candidate TUR01, a tumor necrosis factor-α inhibitor, found long-term stability of the drug substance and drug product were maintained under different temperatures.

Eye on Pharma: Interchangeability Study Results; Express Scripts to Cover Cyltezo; TDM for Idacio

August 3rd 2023

By Skylar Jeremias

Article

Samsung Bioepis and Organon released results from an interchangeability study of its adalimumab biosimilar; Express Scripts announced that it will add Cyltezo as well as 2 other adalimumab biosimilars to its formulary list; Anser Therapeutics will offer therapeutic drug monitoring (TDM) for Idacio.

Why Are Companies Launching Biosimilars With 2 Prices? Julie Reed Explains

July 30th 2023

By Skylar Jeremias

Video

Why are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.